Johnson & Johnson proposed a $5.5 billion settlement to resolve talc cancer lawsuits.
Why it matters: The proposal could close one of the largest toxic-tort fights in U.S. courts and reduce J&J's long-running litigation exposure. It also offers a template for how mass claims over consumer products may be resolved through coordinated settlements.
- J&J said on July 27 it proposed a $5.5 billion settlement resolution.
- The deal is intended to cover about 69,000 federal cases, plus related state-court claims.
- Reuters reported that plaintiffs' law firms confirmed the deal and called it a good resolution after a decade-long court battle.
- A Reuters report on July 22 said a federal judge questioned the strength of the talc claims and warned plaintiffs they needed more specific evidence.
Johnson & Johnson said it has proposed a $5.5 billion settlement resolution to end litigation over claims that its talc-based baby powder and other talc products caused ovarian cancer. The company said the deal would address about 69,000 cases in federal court, along with related state-court claims.
The proposal comes after years of talc litigation and a prior bankruptcy strategy tied to LTL Management LLC. J&J said in its July 27 press release that the agreement is intended to bring an efficient end to the dispute.
Reuters reported that plaintiffs' law firms confirmed the deal and described it as a good resolution after a decade-long court battle. Reuters also reported on July 22 that a federal judge cast doubt on the claims, saying plaintiffs needed more specific evidence or risk dismissal.
The company had previously moved to resolve talc claims through a separate bankruptcy plan. In 2024, J&J proposed a plan it said valued ovarian cancer claimants' recovery at about $6.475 billion over 25 years. J&J stopped selling talc-based Johnson's Baby Powder in the U.S. in 2020.
The deal is not final. It still needs court approval, and the claims it resolves include federal cases and related state matters cited by the company. If claimants reject the proposal or the court does not approve it, the litigation could continue.
By the numbers
- $5.5 billion - J&J's proposed settlement resolution
- About 69,000 - federal cases J&J said the deal is designed to cover
- $6.475 billion - J&J's prior 2024 proposed valuation for an ovarian-cancer talc claims plan
Yes, but: The proposal still faces court review, and the exact scope of claims covered - including how related state cases are handled - is not yet fully resolved.
What's next: A court must review the proposed settlement resolution. The key open questions are whether claimants accept the deal and whether the included federal and related state claims are ultimately approved for release.